IL37 and autoimmune disease: Biological drugs targeting IL-23, either specifically (anti-p19) or in conjunction with IL-12 (anti-p40), have displayed a wide range of antagonistic activities because IL-23 is an important upstream regulator of pathways involved in fibrotic autoimmune diseases [88].